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ABSTRACT 
The periosteum plays an indispensable role in both bone formation and bone defect healing.  This 
study constructed in vitro an artificial periosteum by incorporating osteogenic differentiated bone 
marrow stromal cells (BMSCs) and cobalt chloride (CoCl2)-treated BMSCs. The engineered 
periostea were implanted both subcutaneously and into skull bone defects in SCID mice to 
investigate ectopic and orthotopic osteogenesis and vascularisation. Micro-CT, histomorphometrical 
and immunohistochemical methods were used to assess the ectopic and orthotopic osteogenesis and 
vascularisation of the implanted constructs after two weeks in subcutaneous and four weeks in bone 
defect areas. The results showed that CoCl2 pre-treated BMSCs induced higher degree of 
vascularisation and enhanced osteogenesis within implants in both ectopic and orthotopic areas. 
This study provided a novel approach using BMSCs sourced from the same patient for both 
osteogenic and pro-angiogenic purposes in constructing tissue engineered periosteum to enhance 
vascularized osteogenesis. 
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INTRODUCTION 
Bone defects, especially large bone defects, remain a major challenge in orthopedic surgery [1]. 
Autologous bone transplantation is considered the most effective treatment, but insufficient donor 
tissue, coupled with concerns about donor site morbidity, has hindered this approach in large-scale 
applications.  On the other hand, immunological reactions that would occur in recipients against 
allo or xenogeneic bone grafts impose a major restriction on the clinical application of these 
approaches.  
In both physiological and pathological processes, the periosteum plays an indispensable role in both 
bone formation and defect healing alongside the involvement of various growth factors and 
mechanical loading [2-4].  Periosteum is a dense, dual-layered and highly vascularized connective 
tissue membrane covering cortical bone surfaces [2, 5, 6].  The cambial layer of periosteum 
contains osteoblasts and osteogenic progenitor cells, whereas in the fibrous layer there are collagen 
fibers, fibroblasts and blood vessel networks.  It is the osteogenic function of periosteum that 
determines the rate of de novo postnatal periosteal bone formation and consequently the bone 
strength during the process of growth or defect healing [4].  Transplantation of autogenous or 
allogenous periosteum has been applied successfully in the restoration of various-sized bone defects, 
especially large bone defects [7-9].  Bone healing induced by periosteum has several advantages 
compared to direct bone or bone substitute transplantation, such as healing with a natural bone 
structure, optimal bone integrity in the defect area, appropriate degree of vascularization, and 
minimal ectopic ossification through the defect encasement [7, 8].  However, major concerns in 
the case of autogenous periosteum transplantation include insufficient autologous donor tissues and 
donor site morbidity; and in the case of allogenous transplants, immunological rejection reactions.  
Therefore, in vitro tissue-engineered periosteum, designed to mimic the anatomical structure of 
natural periosteum, may provide a novel approach in the treatment of large bone defects.   
Bone marrow stromal cells (BMSCs) are progenitor cells with the capacity to be differentiated into 
osteogenic lineage following ex vivo expansion and osteogenic induction.  It has been 
demonstrated that these cells are able to regenerate bone tissues upon in vivo transplantation in 
bioactive scaffolds containing hydroxyapatite/tricalcium phosphate (HA/TCP)[10, 11]. However, 
tissue engineered bone substitutes, especially BMSCs delivery constructs, show some difficulties in 
forming functional bone tissues due to the limitation of blood supply after implantation.  A critical 
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problem in using the bone tissue engineering approach to restore large bone defects is that the 
nutrient supply and cell viability at the centre of the scaffold is severely hampered since the 
diffusion distance of nutrients and oxygen for cell survival is limited to 150-200µm [12]. Indeed, 
numerous studies have recently identified that tissue engineered products could only form a limited 
tissue layer on the scaffold surface. Moreover, in the centre of the scaffold, cell density is typically 
low and necrosis may occur. Therefore, the desired tissue engineered bone constructs should 
contain certain pro-angiogenic factors in order to recruit blood vessels into the bone substitutes.  It 
is known that hypoxia will increase the expression of pro-angiogenic factors, such as VEGF, by 
BMSCs, which can help restore the vascularization in ischemic tissues [13, 14]. VEGF is also 
thought to be one of the key factors coupling both vascularization and osteogenesis [15]. CoCl2 is a 
hypoxia mimicking agent, which can activate the hypoxia inducible factor-1 (HIF-1) in 
mesenchymal stem cells and subsequently activate HIF-α target genes including VEGF, EPO, and 
p21[16]. In this study, a dual-layered periosteum was constructed using BMSCs treated by CoCl2 
and osteogenic differentiated BMSCs in a type I collagen scaffold. The osteogenesis and 
vascularization of the tissue engineered periosteum were evaluated subcutaneously and in a critical 
size defect of SCID mice.   
 
MATERIALS AND METHODS 
Cells and cell cultures 
BMSCs were isolated and characterized base on the protocols developed in our previous studies 
[17-19]. Briefly, bone marrow was obtained from hip and knee replacement patients in orthopedic 
department of the Prince Charles Hospital in Brisbane with informed consent and ethics approval 
from the Ethics Committee of Queensland University of Technology. Mononuclear cells (MNCs) 
were isolated from the bone marrow by density gradient centrifugation over Lymphoprep 
(Axis-shield PoC AS, Oslo, Norway) according to the manufacturer’s protocol. The MNCs were 
plated into the culture flasks and cultured in growth media containing Dulbecco’s Modified Eagle 
Medium (DMEM; Invitrogen Pty Ltd., Mt Waverley, VIC, Australia), 10% (v/v) fetal calf serum 
(FCS; InVitro Technology, Noble Park, VIC, Australia) and 1% (v/v) penicillin/streptomycin 
(Invitrogen). The unattached hematopoietic cells were removed through media changes. When 
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reaching the 70-80% confluence, the attached mesenchymal cells were subcultured using 0.25% 
trypsin (Invitrogen) with 1mM EDTA (Invitrogen). Only passages 2-5 (P2-P5) mesenchymal cells 
were used in this study. The medium was changed every three days until the cells were confluent.  
 
Cobalt chloride treatment of BMSCs   
BMSCs were firstly cultured in DMEM until reaching 70-80% confluence in cell culture flask, then 
the media was changed to the DMEM containing 10% (v/v) FCS and 100µM CoCl2 (Sigma Aldrich 
Pty Ltd, Castel Hill, NSW, Australia) one week before the implantation. To observe the VEGF 
expression by the treatment, the real-time polymerase chain reaction (real-time PCR) and western 
blot methods were used on both treated and untreated BMSCs (n=4). Briefly for the real-time PCR, 
total RNA was collected from treated or untreated BMSCs and cDNA was generated using a cDNA 
reverse transcription kit (Invitrogen). A 12.5µl SYBR green q-PCR master mix (AB Applied 
Biosystems, Melbourne, Australia) was mixed with 5 µl Ultrapure water (Invitrogen), 2.5 µl reverse 
and forward primers (Sigma-Aldrich Pty. Ltd, Castle Hill, NSW, Australia) and 2.5 µl cDNA to 
make a 25 µl final reaction system in a 96-well PCR clear plate. The gene expressions of VEGF and 
18s (house keeping gene) were detected by a real time-PCR machine (7300 sequence detection 
system, AB Applied Biosystems, Melbourne, Australia). The sequences of forward and reverse 
primers of each gene are detailed in Table 1. As for the western blot, total cell proteins were 
obtained and 10µg proteins from each sample were used to do western blot analysis. Briefly, the 
protein samples were loaded onto SDS-page gels and run at 125V for 1h. Then the proteins were 
transferred to a nitrocellulous membrane (Pall Corporation, East Hills, NY, USA) using semi-dry 
transfer method. The VEGF and α-tubulin were recognized by VEGF (1:2000, rabbit anti-human, 
Thermo Fisher Scientific, Fremont, CA, USA) and α-tubulin (1:5000, rabbit anti-human, Abcom 
Inc., Cambridge, MA, USA) primary antibodies which then bound to the HRP-conjugated 
anti-mouse or rabbit secondary antibodies (1:10,000, Thermo Fisher Scientific, Fremont, CA, USA). 
Super-signal substrate (Cata.No.34095, Thermo Fisher Scientific, Fremont, CA, USA) was used to 
react with HRP to generate chemiluminescence which left band images on X-ray films. All 
operations were performed under the same conditions.  
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Periosteum construction 
Collagen scaffolds were 1mm-thick bovine type I collagen sheet (Medtronic Australia Pty Ltd, 
North Ryde, NSW, Australia) and customized to a size of 5mm in diameter, then sterilized by 
soaking in 75% ethanol for 10mins, and washed at least three times in PBS prior to cell seeding.  
The scaffold was placed in a well of 96-well cell culture plate. A total of 6×104 BMSCs were 
seeded on top of the scaffolds and cultured in growth media for 24hrs, then changed to osteogenic 
differentiation media containing 10mM β-glycerophosphate, 50µM ascorbic acid and 100nM 
dexamethasone (Sigma) for 2 weeks.  The CoCl2 treated BMSCs (1×105) were then seeded onto 
the other side of the collagen scaffolds. The tissue engineered periosteum was incubated in growth 
media for another three hours, and then implanted in SCID mice subcutaneously or in bone defect 
sites.  
The cell seeding efficiency onto the scaffolds was evaluated by using a NucleoCounter 
(ChemoMetec A/S, DK-3450 Allerød, Denmark) to count the cells attached on the scaffold in 
comparison to the total cells seeded.  The distribution of osteogenic differentiated BMSCs on 
scaffolds was observed by cell nuclei staining. Briefly, the scaffold was fixed in 4% 
paraformaldehyde, embedded in paraffin and 5µm-thick serial sections were cut perpendicular to 
the cell seeding surface using a microtome (Leica Microsystems GmbH, Wetzlar, Germany). Cell 
nuclei were stained with DAPI (Molecular Probes, Invitrogen) and observed under a microscope 
(Carl Zeiss Microimaging GmbH, Gottingen, Germany) at 100 × magnification. The distribution of 
CoCl2-treated BMSCs in the scaffolds was observed by labelling these cells with intra-cellular 
green fluorescent nano-particles (Q-tracker 565; Invitrogen). After labelled cells were seeded onto 
the scaffolds, a 60m thick slice was cryosectioned and stained with DAPI and observed directly 
under a fluorescent microscope (Carl Zeiss Microimaging GmbH, Göttingen, Germany) at 100 × 
magnifications.  
 
Subcutaneous implantation of tissue engineered periosteum in SCID mice  
Animal ethics approval for the use of severe combined immunodeficient (SCID) mice in this 
experiment was granted by the Animal Ethics Committee of Queensland University of Technology. 
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Each group contained four 5-week old male SCID mice (Animal Resources Centre, Canning Vale, 
WA, Australia). The animals were anesthetized with 1mL of ketamine (100mg/mL) and 0.15 mL of 
xylazine (20mg/mL) injected intraperitoneally.  Three small incisions were made longitudinally 
along the central line of the shaved dorsal area, approximately 1cm apart, and subcutaneous pockets 
were made on each side of the incision with a pair of surgical scissors. Each individual pocket had 
one scaffold. Incisions were closed with surgical clips. All animals recovered fully from the surgery 
by the following day and were sacrificed after two weeks. The implants were retrieved for 
following analyses. 
 
Skull defect implantation of tissue engineered periosteum in SCID mice  
A total of twenty-eight 5-week old male SCID mice (Animal Resources Centre) were used.  Skull 
defect model was generated according to our previous studies [20, 21]. Briefly, small incision was 
made longitudinally along the centre line. After the skull bone surface was exposed, the periosteum 
covering the bone surface was totally removed using a dental scraper. A Ø2.5mm defect was then 
created using a dental bur. Care was taken during the drilling to avoid entering the dura. The 
phosphate buffered saline (PBS) was applied onto the drilling site to prevent overheating-related 
damages to local tissues.  The defect was filled with tissue engineered periosteum, covered with 
skin and closed using surgical clips.  All animals recovered fully from the surgery by the following 
day and were sacrificed after four weeks. The skull defect area together with implants was 
harvested. 
 
Assessment of mineralization by micro-CT scanning 
All implants were fixed in 4% paraformaldehyde solution overnight at room temperature and then 
washed in PBS. Cross-sectional scans parallel to the cell seeding surface of subcutaneous or skull 
defect implants were performed in a micro-CT scanner (CT40, SCANCO Medical AG, 
Brüttisellen, Switzerland) at a resolution of 12m and three dimensional (3D) images of implants 
were reconstructed from the scans by the micro-CT system software package. To validate the in 
vivo mineralization of tissue engineered periosteum, scaffolds cultured in vitro or implants without 
pre-seeded cells or carrying only untreated BMSCs were also scanned. For in vitro or 
subcutaneously implanted scaffolds, total volume and average density against hydro-apatite (HA) of 
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mineralization were measured and recorded by the micro-CT system software package for statistical 
analysis. For scaffolds in the skull defect, volume and average density of mineralization within the 
implants (defined by encircling the implant area on each micro-CT slice as area of interest) were 
measured and recorded for statistical analysis.  
 
Mineralization detected by von Kossa staining in subcutaneous implants 
Following micro-CT scanning, subcutaneous implants were embedded in paraffin and 5µm-thick 
serial sections were cut perpendicular to the implants using a microtome (Leica Microsystems 
GmbH). Slices near the central area of the implants were used for von Kossa staining. In brief, after 
slice dewaxing and hydration, Mayer’s haematoxylin (HD Scientific Pty Ltd., Kings Park, NSW, 
Australia) were used for nuclear staining. 5% silver nitrate (Sigma-Aldrich) was added onto each 
slice and exposed to light for at least 30 minutes. Then the slices were briefly washed in distilled 
water and dehydrated in ethanol before being mounted with cover slides. The mineralization was 
observed under a microscope (Carl Zeiss Microimaging GmbH). 
 
Assessment of new bone formation by histological H&E staining 
Following micro-CT scanning, skull defect implants were decalcified in 10% EDTA and embedded 
in paraffin and 5µm-thick serial sections were cut perpendicular to the implants using a microtome 
(Leica Microsystems GmbH).  Slices near the central area of the implants were used for the H&E 
staining. Briefly, following slice dewaxing and hydration, Mayer’s haematoxylin (HD Scientific Pty 
Ltd.) were used for nuclear staining. After dehydration in alcohol with up-grading concentrations, 
cell plasma and extracellular matrix were stained by eosin (HD Scientific Pty Ltd.). Based on H&E 
staining, de novo bone formation within the implants was observed and the area of new bone tissues 
on each slice was measured using AxioVision software (Carl Zeiss Microimaging GmbH). Three 
measurements from each implant were averaged and used for statistical analysis. 
 
Assessment of vascularization and new bone formation using immunohistochemical staining   
Slices near the central area of the implants were used for the immunohistochemical staining.  A 
von Willebrand factor (vWF) antibody (mouse anti-human, Chemicom International Inc., Temecula, 
CA) was used to identify the presence of endothelial cells in the implants. An alkaline phosphatase 
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(ALP) antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used to confirm newly 
formed bone matrix in implants. In brief, following slice dewaxing and hydration, endogenous 
peroxidase activity was quenched by incubating the sample slices with 3% H2O2 for 20 minutes 
then blocked with 10% swine serum for 1 hour.  The samples were incubated with the vWF 
primary antibody (1:300) or ALP antibody (1:200) overnight at 4oC, followed by incubation, at 
room temperature, with a biotinylated swine-anti-mouse, rabbit, goat secondary antibody (DAKO 
Multilink, CA, USA) for 15 minutes, and then with horseradish perioxidase-conjugated 
avidin-biotin complex (DAKO Multilink, CA, USA) for another 15 minutes. The antibody 
complexes were visualized by the addition of a buffered diaminobenzidine (DAB) substrate for 4 
minutes.  Mayer’s haematoxylin (HD Scientific Pty Ltd.) were used for counter staining. The 
number of vWF+ blood vessels were counted and normalized to the area of the implant on each slice.  
Three measurements from each implant were averaged and used for statistical analysis.  
Double staining of both vWF and calcium on subcutaneous implants 
Double staining with vWF antibody and von Kossa method (calcium staining) was performed on 
subcutaneous implants to determine the relationship between osteogenesis and vascularization.  In 
brief, following vWF staining, 5% silver nitrate (Sigma-Aldrich) was added onto each slice and 
exposed to light for at least 30 minutes and the slices briefly washed in distilled water and 
dehydrated in ethanol before being mounted with cover slides.   
 
Statistical analysis 
Analysis was performed using SPSS software (SPSS Inc, Chicago, Il, USA). All the data were 
analyzed using one-way ANOVA or Friedman test for group differences. The significance level was 
set at p ≤ 0.05.   
 
RESULTS 
VEGF expression in CoCl2-treated BMSCs 
The VEGF gene expression of CoCl2-treated BMSCs was assessed by real time q-PCR. BMSCs 
cultured in CoCl2-induced hypoxia condition expressed significantly higher level of VEGF than that 
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in normal culture condition (p<0.05)(Fig.1A). The intracellular VEGF proteins identified by 
western blot further confirmed the upregulation of VEGF in CoCl2-treated BMSCs (Fig.1B). 
 
Tissue engineered periosteum 
Collagen sponges were used as scaffold for the construction of tissue engineered periosteum. A 
total of 6 × 104 BMSCs were firstly seeded onto the collagen scaffolds (Fig. 2A). The cell seeding 
efficiency was 92.3 ± 2.5% (Fig. 2C). After two weeks of osteogenic differentiation, CoCl2-treated 
BMSCs were seeded onto the other side of the scaffolds (Fig.2B). The cell seeding efficiency of 
CoCl2-treated BMSCs was 85.3 ± 5.0% (Fig. 2C). The collagen scaffolds with both osteogenic 
differentiated and CoCl2-treated BMSCs formed a generally dual-layered cell and matrix construct 
similar to periosteum structure with one layer of osteogenic cells and the other layer of 
pro-angiogenic cells. The histology of the tissue engineered periosteum revealed that after the initial 
cell seeding, cells attached to the collagen fibres and distributed evenly within the scaffold (Fig. 
2A). Slices from cryosectioning revealed a dual-layered structure with most fluorescence-labelled 
CoCl2-treated BMSCs on one side of the construct and osteogenic cells on the other side of scaffold 
(Fig. 2B).     
 
Enhanced vascularisation and mineralization by CoCl2-treated BMSCs in subcutaneously 
implanted cell constructs 
General observation on the subcutaneous implants showed that the construct containing 
CoCl2-treated BMSCs attracted more blood vessels growing around the construct compared with 
other constructs (Fig.3A-C). Further vWF staining on implant slices confirmed that scaffolds 
containing CoCl2-treated BMSCs had higher degree of vascularisation (Fig.3D-H, p<0.05, 
Friedman test).  
Micro-CT scanning and 3D reconstruction revealed that substantial amount of mineralization was 
found in the implants containing osteogenic differentiated BMSCs (Fig.4 B-D). The constructs 
containing both osteogenic differentiated and CoCl2-treated BMSCs showed the highest volume of 
mineralized areas (Fig.4D & I, p<0.05, Friedman test), although no significant differences were 
found in the average density of mineralized areas between groups (Fig.4J, p>0.05, Friedman test). 
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No mineralization was found in the scaffolds without pre-seeded cells or containing undifferentiated 
BMSCs (Fig.4I). Very limited mineralization was detected in vitro-cultured constructs (Fig.4A&I). 
von Kossa staining on implants confirmed CoCl2-treated BMSCs significantly enhanced the 
mineralization within the implants (Fig.4E-G). However, despite the mineralization in the implants, 
no histological bone tissue was detected in all subcutaneously transplanted constructs based on the 
H&E staining at this time point (Fig.4H).  
In subcutaneous implants, von Kossa and vWF double staining showed a close relationship between 
the mineralization and blood vessel distribution (Fig.5). It was noted that micro-blood vessels grew 
around and into the mineralized areas (Fig.5). 
 
Enhanced new bone formation and vascularization by CoCl2-treated BMSCs in skull defect  
In skull defects, general observation revealed that the defects filled with scaffolds carrying 
osteogenic differentiated BMSCs (alone or together with other cells) showed much better repair 
than control groups of collagen scaffold alone or impregnated with undifferentiated BMSCs(Fig.6). 
Micro-CT scanning and 3D reconstruction showed that the implants carrying osteogenic 
differentiated BMSCs plus CoCl2-treated BMSCs had significantly higher volume of mineralized 
areas than other implants (Fig.7K, p<0.001, one-way ANOVA test), while no significant difference 
was found in the average density of mineralized areas among different groups (Fig.6L, p>0.05, 
one-way ANOVA test). The 3D reconstructed defect area (Fig.6 A-D) showed that the defects filled 
with implants carrying osteogenic differentiated BMSCs plus CoCl2-treated BMSCs healed much 
better than other groups. H&E staining on slices revealed that the implants carrying osteogenic 
differentiated BMSCs plus CoCl2-treated BMSCs had significantly more newly formed bone tissues 
than other implants (Fig.7E-G&M, p<0.001, one-way ANOVA test), and the defects were almost 
bridged by the newly formed bone tissues (Fig.7G). Interestingly, the de novo bone tissue formed 
along and incorporated the collagen fibers of the scaffold (Fig.7 H&I). Immunohistochemical 
staining against ALP further confirmed the newly formed bone tissue within implants was 
surrounded by ALP+ osteoblasts (Fig.7J).  
General observation also showed that the implants carrying both osteogenic differentiated BMSCs 
and CoCl2-treated BMSCs attracted blood vessels to grow into the defect area (Fig.6E&F). Further 
vWF staining on implant slices confirmed that scaffolds containing CoCl2-treated BMSCs had 
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higher degree of vascularisation (Fig.8, p<0.001, one-way ANOVA test). vWF+ micro-blood vessels 
were found gathering around the de novo bone tissues and involved into the newly formed bone 
tissues (Fig.8 D-F). 
   
DISCUSSION 
As recently pointed out in a review by Zhang et el, periosteum engineering could assist in structural 
de novo bone formation and is therefore a promising method for bone defect restoration [22].  
Although much work has focused on the structure, cell populations and osteogenic mechanisms 
within the periosteum [4, 23-26], few, if any, references were found which addresses engineered 
periosteum containing different cell populations such as osteogenic and pro-angiogenic cells, not to 
mention an in vivo assessment of any such constructs.  To the best of our knowledge, this is the 
first attempt to construct an artificial bi-layered periosteum with BMSCs dedicated into two 
different cell functions – osteogenic and pro-angiogenic.  Previous studies concerning artificial 
periosteum have described structures with a single cell population, and therefore differ considerably 
from the natural structure of real periosteum [27-29].   The obvious drawback of these approaches 
is the lack of information about osteogenic and pro-angiogenic cell interactions in forming a 
vascularised bone.  In the experiment presented here, both osteogenic (BMSCs derived osteoblasts) 
and pro-angiogenic cells (CoCl2-pre-treated BMSCs) were seeded onto either side of a collagen 
membrane, trying to mimic the distribution of cell populations in physiological structure of 
periosteum.   
 
Although there are many other cell populations residing within the real periosteum, osteogenic and 
endothelial cells are the major and most important cell populations [30, 31] and the interactions 
between the osteogenesis and vascularisation determine the osteogenic function of periosteum to a 
large extent. To enhance the vascularisation of engineered tissues and organs, three different 
approaches are most often used: i) autogenous or allogenous endothelial cells which could be 
directly incorporated into the host blood vessel networks[32, 33]; ii) impregnate pro-angiogenic 
growth factors, such as VEGF, bFGF, and PDGF into the scaffold to incur the new blood vessel 
ingrowth[15, 34]; iii) incorporate gene vectors (plasmid or virus) encoding pro-angiogenic growth 
factors or cells transfected by those gene vectors within scaffolds to attract new blood vessels[35].  
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All these approaches show their disadvantages in the potential in vivo applications, such as the 
difficulties in isolation of endothelial cells from the host and immunological reactions to allogenous 
endothelial cells, the low growth rate of autologous endothelial cells in vitro, biological safety 
concerns about the gene vectors or transfected cells and unstable temporal and spatial release of 
pro-angiogenic growth factors in defect areas. Recently studies have tried to induce autologous 
bone marrow-derived mesenchymal stem cells to differentiate towards endothelial cells, but the 
results so far are still elusive and uncertain[36, 37]. Interestingly, it has been reported that either low 
oxygen pressure or hypoxia-mimic agents, such as CoCl2 or desferrioxamine, can upregulate the 
expression of pro-angiogenic growth factors, VEGF in particular, in a variety of cells including 
BMSCs[38, 39]. The hypoxia pre-treated BMSCs had been successfully used to help re-vascularize 
the ischemic or infarcted muscles in animal models[10, 13]. In this study, BMSCs were pre-treated 
with hypoxia-mimic agent CoCl2 and the VEGF expression after treatment was found to be 
increased by around 5 folds. VEGF is the most important growth factor involved in both angiogenic 
and osteogenic processes [40-42], Therefore, in this study CoCl2 pre-treated BMSCs were 
incorporated together with BMSCs-derived osteoblasts into the engineered periosteum model for 
the generation of vascularized bone in vivo.  
 
Two different animal models are often used to assess the in vivo osteogenic ability of engineered 
tissues: subcutaneous (ectopic) and bone defect (orthotopic) osteogenesis models. In this study, both 
models were included. During pathological and physiological osteogenesis, two distinct patterns of 
bone formation are involved – intramembranous and endochondral ossification.  Intramembranous 
ossification predominantly takes place in the periosteum during normal bone formation in which 
osteoprogenitor cells differentiate directly into osteoblasts laying down new bone tissues [43].  
Although much has been reported about both in vivo and in vitro interactions between osteogenesis 
and vascularization [15, 32], the knowledge of in vivo interactions between osteogenesis and 
vascularisation, especially those during early osteogenic stages and related to periosteal 
intramembranous ossification, is still very much patchy.  Early stage histological and 
ultrastructural changes in microvessels of periosteal calluses after bone facture, using the light and 
electron microscope, has been described previously, but no quantitative data about the interaction 
between osteogenesis and vascularization was provided [44].  In the present study, observations 
and assessments about the osteogenesis and vascularisation at a relatively early stage in the 
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engineered periosteum were performed two weeks after subcutaneous implantation and four weeks 
after skull defect implantation.  Osteogenesis and vascularization were then quantified using 
micro-CT scanning, histological and immunohistochemical methods [45].  Our findings showed 
that subcutaneously implanted scaffolds presented more extensive calcification compared with 
scaffolds prior to in vivo implantation, while in skull defects de novo bone tissues were evident. 
Another noteworthy point is that in the skull defect naked collagen implants or implants carrying 
only BMSCs were almost degraded and generated very limited new bone tissues within the defect 
when compared with implants carrying BMSCs-derived osteoblasts. This phenomenon suggested 
that new bone formation may require the orchestration of an osteogenesis-favouring environment, 
appropriate calcium precipitation on the collagen fibres and osteogenic cells.  As for the 
vascularisation, CoCl2 pre-treated BMSCs helped significantly increase blood vessel density in both 
subcutaneously and skull defect implanted scaffolds compared with others. The upregulated VEGF 
expression by CoCl2 pre-treated BMSCs could stimulate the osteogenesis of BMSCs-derived 
osteoblasts after the cells were seeded and this osteogenic process could be even more enhanced by 
subsequently enhanced vascularization. The calcium-vWF double staining and vWF+ micro blood 
vessels surrounding de novo bone tissues also revealed the close relationship between the 
osteogenesis and vascularization. To confirm the pro-osteogenic and pro-angiogenic effects of 
CoCl2 pre-treated BMSCs, untreated BMSCs were used together with BMSCs-derived osteoblasts 
as an internal control. The findings in this study showed that the addition of untreated BMSCs did 
not significantly help the in vivo ectopic or orthotopic osteogenesis by BMSCs-derived osteoblasts 
and vascularization.  
 
Conclusion: Based on the findings of this experimental study, it could be concluded that CoCl2 
pre-treated BMSCs can enhance the vascularization in both ectopic and orthotopic osteogenesis in a 
periosteum model. This study provides a novel approach using BMSCs sourced from the same 
donor for the regeneration of vacularized bone tissue.   
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